GenMark Diagnostics, Inc. Form 8-K August 11, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2014

#### GENMARK DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34753

Delaware 27-2053069
(State or other jurisdiction (I.R.S. Employer of incorporation) Identification No.)

5964 La Place Court Carlsbad, California (Address of principal executive offices, including zip code)

760-448-4300

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The following disclosure is provided pursuant to subsection (b) of Item 5.02 of Form 8-K.

Christopher Gleeson, the Chairman of the Board of Directors (the "Board") of GenMark Diagnostics, Inc. (the "Company"), retired from the Board effective August 6, 2014 to attend to personal health matters. Effective upon Mr. Gleeson's retirement from the Board, the Board appointed Jim Fox, Ph.D., the Company's former Vice Chairman and Lead Independent Director, as Chairman of the Board.

Mr. Gleeson's decision to retire was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

The Company issued a press release on August 11, 2014 announcing Mr. Gleeson's retirement, a copy of which is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits Exhibit No. Description

99.1 Press release dated August 11, 2014.

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

GENMARK DIAGNOSTICS, INC.

Date: August 11, 2014 /s/ Eric Stier

Eric Stier

Senior Vice President, General Counsel and Secretary

# EXHIBIT INDEX

Exhibit No. Description

99.1 Press release dated August 11, 2014.